drugset / Trial / NCT02420587
AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is learn how AMG208 may help to control prostate cancer that has spread to the bone. The safety of the drug will also be studied.
Timeline
- Start
- 2014-10
- Primary completion
- 2019-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMG 208 | Small molecule | 400 mg | Oral |